Cargando…
Is high-dose glucocorticoid beneficial in COVID-19?
High-dose glucocorticoids are not currently recommended for treating severe COVID-19 pneumonia https://bit.ly/39VQ3O8
Autores principales: | Muthu, Valliappan, Sehgal, Inderpaul Singh, Prasad, Kuruswamy Thurai, Agarwal, Ritesh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7842156/ https://www.ncbi.nlm.nih.gov/pubmed/33509962 http://dx.doi.org/10.1183/13993003.00065-2021 |
Ejemplares similares
-
High-dose versus low-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: an open-label, randomised trial (the COLDSTER trial)
por: Dhooria, Sahajal, et al.
Publicado: (2022) -
Reply: Is high-dose glucocorticoid beneficial in COVID-19?
por: Edalatifard, Maryam, et al.
Publicado: (2021) -
Impact of COVID-19 pandemic on tuberculosis notifications in India
por: Aggarwal, Ashutosh Nath, et al.
Publicado: (2022) -
Where there is a balloon, there is a way!
por: Muthu, Valliappan, et al.
Publicado: (2020) -
The Reversed Halo Sign and the Bronchus Sign: The Eyes See Only What the Mind Knows
por: Muthu, Valliappan, et al.
Publicado: (2019)